Nov 16, 2022 / 04:30PM GMT
Paul Matteis - Stifel Financial Corp. - Analyst
Great. I think we're ready to get started with this session here. Happy to be hosting the Dyne Therapeutics team, Oxana and Jonathan; Chief Scientific Officer and Head of Business Development, right?
Jonathan McNeill - Dyne Therapeutics, Inc. - SVP, Business Development
Yes.
Paul Matteis - Stifel Financial Corp. - Analyst
Great. Thanks for joining. So Dyne is a muscle focused company with two studies ongoing, both going to have some data next year. Either Jonathan or Oxana, do you wanted to just set the stage and give us an update on the DMD and DM1 programs and then we can do Q&A?
Jonathan McNeill - Dyne Therapeutics, Inc. - SVP, Business Development
Yes, sure. So first, thanks for having us here today. It is really a great time to be able to share an update on Dyne. Very exciting time for the company. Before we get started, we will be making some forward-looking statements today, so please refer to our SEC filings for
Dyne Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers